Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study is looking at Chronic Obstructive Pulmonary Disease, which is a long-term lung condition that makes it hard to breathe and can cause flare-ups called exacerbations. The study involves people who have this lung disease and have experienced these flare-ups in the past. Participants will receive either tozorakimab, which is an investigational medication given as an injection under the skin, or placebo. All participants will continue taking their regular lung medications, including salbutamol, which is a quick-relief inhaler that helps open the airways when needed.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Transition from previous study

    This study is a continuation for participants who have already completed the treatment period in a previous study called OBERON or TITANIA.

    To enter this extension study, the last dose of medication from the previous study must have been received within the past 12 weeks.

    Participation in this study is only possible if treatment in the previous study was completed without early discontinuation of the study medication.

  2. Step 2

    Initial visit and screening procedures

    At the first visit, informed consent will be signed, confirming voluntary participation in the study.

    If applicable, a urine pregnancy test will be performed, which must be negative to continue in the study.

    Confirmation will be required that the same contraceptive methods agreed upon in the previous study will continue to be used throughout this study.

  3. Step 3

    Treatment period with study medication

    The study medication will be either tozorakimab or placebo, assigned randomly. The placebo is an inactive substance that looks identical to the actual medication.

    Tozorakimab or placebo will be administered as an injection under the skin (subcutaneous injection).

    The study medication will be given in addition to the regular medications for chronic obstructive pulmonary disease, which is a long-term lung condition that makes breathing difficult.

    Treatment will continue for an extended period as part of this long-term study, which is expected to run until February 2026.

    Throughout the treatment period, regular visits will be scheduled to monitor health status and any changes in the condition.

  4. Step 4

    Use of rescue medication

    Salbutamol will be available as a rescue medication if needed. This medication is inhaled and helps to quickly relieve breathing difficulties.

    Salbutamol is used when symptoms suddenly worsen or when quick relief is needed.

  5. Step 5

    Monitoring and assessments during the study

    Regular assessments will be conducted to evaluate how well the study medication is working and to monitor for any side effects.

    The study will track the number and severity of exacerbations, which are sudden worsening episodes of lung disease symptoms such as increased coughing, shortness of breath, or mucus production.

    Particular attention will be paid to severe exacerbations, which are episodes that require hospitalization or emergency room visits.

    Blood samples may be taken periodically to measure the levels of study medication in the body and to check if the body has developed any immune response to the medication.

    Safety monitoring will continue throughout the entire study period to assess the long-term tolerability of the treatment.

  6. Step 6

    Completion of the study

    The study will continue until the planned end date or until the study physician determines that participation should end.

    A final assessment will be conducted to evaluate the overall response to treatment and any long-term effects.

    Information collected during the study will be used to determine whether the study medication is effective in reducing severe lung disease episodes over the long term.

Who can join the trial?

6 criteria

  • You must have completed the full treatment period in the previous OBERON or TITANIA studies without stopping the study medicine early
  • You must have received your last dose of study medicine in the previous studies within the past 12 weeks, which means within the last three months
  • You must not have withdrawn or dropped out from the previous study
  • If you are a woman who is able to become pregnant, you must have a negative urine pregnancy test, which is a test that checks if you are pregnant using a urine sample, at your first visit
  • You must be willing to continue using the same birth control methods that you agreed to use in the previous OBERON or TITANIA studies to prevent pregnancy
  • You must be able to understand the study information and sign a document showing you agree to take part in the study, which is called informed consent

Who cannot join the trial?

3 criteria

  • The source data does not contain specific exclusion criteria, which are reasons why a patient cannot participate in the study
  • Without detailed exclusion criteria information, it is not possible to list specific medical conditions, medications, or situations that would prevent participation
  • Generally, clinical trials have exclusion criteria to ensure patient safety and study accuracy, but these specific details are not provided in the available information
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Tozorakimab is an investigational medication being studied as an add-on treatment for people with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations. Exacerbations are periods when COPD symptoms suddenly get worse. This medication is given in addition to standard care treatments to see if it can help reduce the number of severe flare-ups in people who used to smoke.

A placebo is an inactive substance that looks like the real medication but contains no active treatment. It is used in this study to compare against tozorakimab to help researchers determine if the actual medication is effective.

What is already known about the treatment

Tozorakimab – Tozorakimab is an investigational medication currently being studied in clinical trials for the treatment of Chronic Obstructive Pulmonary Disease (COPD), particularly in patients who experience frequent flare-ups of their condition. This medication is being tested as an add-on therapy to standard care treatments, with the goal of reducing severe exacerbations in former smokers with COPD. The drug is administered as part of a long-term treatment plan and works by targeting specific molecules in the body that contribute to inflammation and worsening of lung disease. Tozorakimab belongs to a class of medications called monoclonal antibodies, which are designed to block certain proteins involved in the disease process.

Investigated diseases

Chronic Obstructive Pulmonary Disease – Chronic Obstructive Pulmonary Disease is a long-term lung condition that makes breathing difficult. The airways in the lungs become narrowed and damaged, which blocks airflow and makes it hard to get air in and out. People with this disease often experience coughing, wheezing, shortness of breath, and chest tightness. The condition usually develops slowly over many years, most commonly in people who smoke or have smoked. As the disease progresses, everyday activities like walking or climbing stairs become increasingly difficult due to breathing problems. The lungs continue to deteriorate over time, leading to more frequent episodes called exacerbations where symptoms suddenly worsen.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-501063-41-00Protocol codeD9180C00008Estimated enrolment1 770 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).